

New quinoxaline derivatives as dual Pim-1/2 kinase inhibitors: design, synthesis and biological evaluation

Bruno Oyallon ¹, Marie Brachet-Botineau ², Cédric Logé ³, Thomas Robert ^{4,5}, Stéphane Bach ^{4,5,6}, Sajida Ibrahim ⁷, William Raoul ^{7,8}, Cécile Croix ¹, Pascal Berthelot ⁹, Jean Guillon¹⁰, Noël Pinaud ¹¹, Fabrice Gouilleux ², Marie-Claude Viaud-Massuard ¹, Caroline Denevault-Sabourin ^{1,*}

¹ EA GICC - ERL 7001 CNRS « Groupe Innovation et Ciblage Cellulaire », Team « Innovation Moléculaire et Thérapeutique », University of Tours, F-37200 Tours, France; caroline.denevault@univ-tours.fr

² CNRS ERL7001 LNOx « Leukemic Niche and redOx metabolism » - EA GICC, University of Tours, F-37000 Tours, France; fabrice.gouilleux@univ-tours.fr

³ Université de Nantes, Nantes Atlantique Universités, Département de Chimie Thérapeutique, Cibles et Médicaments des Infections et du Cancer, IICIMED- EA1155, Institut de Recherche en Santé 2, F-44200 Nantes, France; cedric.loge@univ-nantes.fr

⁴ Sorbonne Université, CNRS, UMR8227, Integrative Biology of Marine Models Laboratory (LBI2M), Station Biologique de Roscoff, F-29680 Roscoff, France; bach@sb-roscott.fr

⁵ Sorbonne Université, CNRS, FR2424, Plateforme de criblage KISSf (Kinase Inhibitor Specialized Screening facility), Station Biologique de Roscoff, F-29680 Roscoff Cedex, France; trobert@sb-roscott.fr

⁶ Centre of Excellence for Pharmaceutical Sciences, North-West University, Private Bag X6001, Potchefstroom 2520, South Africa

⁷ EA GICC - ERL 7001 CNRS « Groupe Innovation et Ciblage Cellulaire », Team « Pharmacologie des Anticorps Thérapeutiques Chez l'Homme », University of Tours, F-37200 Tours, France; william.raoul@univ-tours.fr

⁸. N2C UMR 1069, University of Tours, Inserm, F-37032 Tours, France

⁹ UMR-S 1172 - JPArc - Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, University of Lille, Inserm, CHU Lille, F-59000 Lille, France

¹⁰ University of Bordeaux, INSERM U12132 - UMR CNRS 5320, ARNA Laboratory, F-33076 Bordeaux, France; jean.guillon@u-bordeaux.fr


¹¹ University of Bordeaux, ISM – CNRS UMR 5255, F-33405 Talence, France; noel.pinaud@u-bordeaux.fr

* Correspondence: caroline.denevault@univ-tours.fr; Tel.: +33 2 47-36-72-31 (C.D.S.)


1.	NMR spectra.....	2
2.	Mammalian protein kinase assays.....	22
2.1.	Inhibition curves of compound 5c	22
2.2.	Inhibition curves of compound 5e	23

1. NMR spectra


¹H NMR of compound 5a




¹³C NMR of compound 5a




¹⁹F NMR of compound 5a




¹H NMR of compound 5b




¹³C NMR of compound 5b




¹⁹F NMR of compound **5b**




¹H NMR of compound 5c




¹³C NMR of compound 5c




¹H NMR of compound 5d




¹³C NMR of compound 5d




¹H NMR of compound 5e




¹³C NMR of compound 5e




¹H NMR of compound 5f




¹³C NMR of compound 5f




¹H NMR of compound 5g




¹³C NMR of compound 5g




¹⁹F NMR of compound 5g




¹H NMR of compound 5h



¹³C NMR of compound 5h



¹⁹F NMR of compound 5h



2. Mammalian protein kinase assays

2.1. Inhibition curves of compound **5c**




Figure S1. Inhibition curves of compound **5c** on *HsPim1* (A), *HsPim2* (B), *RnDYRK1A* (C), and *HsGSK3 β* (D).

2.2. Inhibition curves of compound **5e**




Figure S2. Inhibition curves of compound **5e** on *HsPim1* (A), *HsPim2* (B), *RnDyrk1A* (C), and *HsGSK3β* (D).